C.I. Pigment Red 104

994

995.68472

235-759-9

3077

DTXSID9051321

Fine dark orange or light red powder|Hue depends on the proportion of molybdate, crystal form, and particle size. /Molybdate Red and Molybdate Orange/

249

0.00000

DryPowder; PelletsLargeCrystals

Index of refraction = 2.3-2.7/Molybdate Red and Molybdate Orange/

<0.01 mg/L at 20 °C

5 to 7 at 100 g/L at 25 °C

5.4-6.3 g/cu cm /Molybdate Red and Molybdate Orange/

Solid soln of lead chromate, lead molybdate and lead sulfate|Resistant properties of molybdenum orange: alkali, good; acid, fair; exterior durability, good; heat resistance, poor.|Composition of most molybdate orange formulations = lead chromate (PbCrO4, 69-80%), lead molybdate (PbMoO4,9-15%), lead sulfate (PbSO4,3-7%), lead oxide, and other components (3-13%).|Pigment particles can be coated with metal oxides, metal phosphates, silicates that yield stabilized pigments with high color brilliance, as well as resistance to light, weathering, sulfur dioxide, and temperature. Contains a very low content of acid soluble lead.|The various hues of ... molybdate oranges depend on the interrelationship of three factors: chemical composition, crystal structure, and particle size /Lead chromate pigments/

61-33-40-50/53-62

53-45-60-61

T,N

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.

/Incompatible with/ strong oxidizers. /Molybdenum, insoluble compounds, (as Mo)/

USEPA, Office of Drinking Water; Criteria Document (Draft): Molybdenum (1985)

|Danger|H350: May cause cancer [Danger Carcinogenicity]|P201, P202, P260, P273, P281, P308+P313, P314, P391, P405, and P501|H350 (99.76%): May cause cancer [Danger Carcinogenicity]|Aggregated GHS information provided by 418 companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|H317: May cause an allergic skin reaction [Warning Sensitization, Skin]|P201, P202, P260, P261, P271, P272, P273, P280, P281, P302+P352, P304+P340, P308+P313, P311, P314, P321, P333+P313, P363, P391, P403+P233, P405, and P501|P201, P202, P260, P261, P264, P270, P272, P280, P281, P285, P302+P352, P304+P341, P307+P311, P308+P313, P314, P321, P333+P313, P342+P311, P363, P405, and P501

Respirators may be used when engineering and work practice controls are not technically feasible, when such controls are in the process of being installed, or when they fail and need to be supplemented. Respirators may also be used for operations which require entry into tanks or closed vessels, and in emergency situations. If the use of respirators is necessary, the only respirators permitted are those that have been approved by the Mine Safety and Health Administration (formerly Mining Enforcement and Safety Administration) or by the National Institute for Occupational Safety and Health. /Soluble Molybdenum cmpd (as Molybdenum); Molybdenum and insoluble molybdenum cmpd/|Respirator selection: Upper limit devices recommended by ACGIH: Up to 50 mg/cu m: Any dust and mist respirator; up to 100 mg/cu m: any dust and mist respirator except single-use and quarter mask respirators or any supplied air respirator or any self contained breathing apparatus; up to 250 mg/cu m: any powered air purifying respirator with a dust and mist filter or any supplied air respirator operated in a continuous flow mode; up to 500 mg/cu m: any air purifying full facepiece respirator with a high efficiency particulate filter or any powered air purifying respirator with a tight fitting facepiece and a high efficiency particulate filter or any supplied air respirator with a tight fitting facepiece operated in a continuous flow mode or any self contained breathing apparatus with a full facepiece or any supplied air respirator with a full facepiece; up to 7500 mg/cu m: any supplied air respirator with a half mask and operated in a pressure-demand or other positive pressure mode; Emergency or planned entry in unknown concentration or IDLH conditions: any self contained breathing apparatus with a full facepiece and operated in a pressure demand or other positive pressure mode or any supplied air respirator with a full facepiece and operated in a pressure demand or other positive pressure mode in combination with an auxiliary self contained breathing apparatus operated in pressure demand or other positive pressure mode; Escape: any air purifying full facepiece respirator with cartridge(s) providing protection against the compound of concern and having a high efficiency particulate filter or any appropriate escape type self contained breathing apparatus. /Molybdenum, insoluble compounds (as Mo)/

REMOVAL OF DISSOLVED & SUSPENDED SOLID POLLUTANTS FROM WASTEWATER MANUFACTURE OF MOLYBDATE ORANGE PIGMENTS IS DISCUSSED. USE OF ION EXCHANGERS FOR TREATMENTS IS DESCRIBED.

... A complete respiratory protection program should be instituted which incl regular training, maintenance, inspection, cleaning, and evaluation. /Sol Molybdenum compounds (as Mo); Molybdenum and insoluble molybdenum compounds/

LD50 Rat oral less than 5000 mg/kg

... by ingestion

Carcinogens

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/|/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand-valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR as necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Inorganic acids and related compounds/|For more Antidote and Emergency Treatment (Complete) data for C.I. PIGMENT RED 104 (6 total), please visit the HSDB record page.

/SIGNS AND SYMPTOMS/ Potential symptoms as a result of exposure: Respiratory & nasal septum irritations; leukocytosis, leukopenia, monocytosis, eosinophilia; eye injury, conjunctivitis, skin injury, sensitization dermatitis. /Lead chromate/|/SIGNS AND SYMPTOMS/ OCCUPATIONAL EXPOSURE TO CHROMIUM CMPD (CR6+) CAUSES DERMATITIS, PENETRATING ULCERS ON HANDS & FOREARMS, PERFORATION OF NASAL SEPTUM, & INFLAMMATION OF LARYNX & LIVER. /LEAD CHROMATE/|/CASE REPORTS/ In 1954, the average air lead level in a privately owned lead plant was 1000 times the current standard, and all female employees were found to have lead poisoning. Lead poisoing was no longer found among employees after the plant merged into a government enterprise. Females were found to be more sensitive to lead poisoning than were men. Rates of threatened abortions were significantly higher among female workers exposed to lead chromate, and nursing babies of mothers with lead poisoning were diagnosed as having lead poisoning. /Lead chromate/|/EPIDEMIOLOGY STUDIES/ In 1975, five manufacturers of chromate pigment in Japan were examined in a study of the carcinogenicity of chromates. These companies were producing lead chromate, zinc chromate, molybdate orange and/or strontium chromate. The current study covers a cohort of 666 workers involved in the manufacture of chromate pigment for at least 1 year between 1950 and 1975. The workers were followed up for 15-40 years, until 1989. Many previous reports have found an excess lung cancer risk among workers involved in the manufacture of chromate pigments and chromate chemicals. In the current study, subjects were classified on the basis of years worked, years of observation, characteristics of company, type of work engaged in for the longest period of time, and involvement in the manufacture of zinc chromate. Mortality was compared with that of all Japanese males by means of the person-year method. The route of exposure was primarily inhalation through the respiratory system. None of the results showed statistically significant differences that would suggest an excess risk for malignant neoplasms, particularly lung cancer, among workers engaged in the manufacture of chromate pigment in Japan.|For more Human Toxicity Excerpts (Complete) data for C.I. PIGMENT RED 104 (12 total), please visit the HSDB record page.

molybdate orange

ESSENTIALLY 100% AS A PIGMENT

... mixed-phase pigments ... Most commercial products have a MoO3 content of 4-6% /Molybdate Red and Molybdage Orange/

Custom compounding of purchased resin|C.I. Pigment Red 104: ACTIVE|SP - indicates a substance that is identified in a proposed Significant New Use Rule.|Does not meet American National Standards Institute Specifications Z 66.1 (1964)|Molybdate oranges are tetragonal solid solutions of lead sulfate, lead chromate, and lead molybdate. /Chromate pigments/|Composition (wt %) (Analyte, Specification, Theory, Actual Min): PbCr4O4, 70, 82.3; PbMoO4, 8, 14.9; PbSO4, not specified, 2.8; Total Foreign Material 12|Molybdate orange primary constituents: PbCrO4 Formula Weight = 323.2 g/mole, PbMoO4 Formula Weight = 367.1 g/mole, PbSO4 Formula Weight =303.3 g/mole

Health Hazards -> Carcinogens